
Pharos iBio
Founded Year
2016Stage
Series C | AliveTotal Raised
$35.41MLast Raised
$15.91M | 2 yrs agoAbout Pharos iBio
Pharos iBio is a drug discovery and development biotech company specializing in analyzing big data based on IT technology. The company uses artificial intelligence techniques to predict the various properties of a compound, and introduces a low-cost and efficient new drug development system. Pharos iBio is focusing on the development of new drugs with orphan and rare diseases, which can shorten the development period and have a high success rate of NDA approval.
Expert Collections containing Pharos iBio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pharos iBio is included in 1 Expert Collection, including Artificial Intelligence.
Artificial Intelligence
10,944 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Pharos iBio Patents
Pharos iBio has filed 5 patents.
The 3 most popular patent topics include:
- Cancer treatments
- Chemical bonding
- Experimental cancer drugs

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/29/2019 | Radiation therapy, Medical physics, Cancer treatments, Transcription factors, Acute myeloid leukemia | Application |
Application Date | 5/29/2019 |
---|---|
Grant Date | |
Title | |
Related Topics | Radiation therapy, Medical physics, Cancer treatments, Transcription factors, Acute myeloid leukemia |
Status | Application |
Latest Pharos iBio News
Aug 28, 2023
닫기 Pharos iBio, an AI-backed new drug developer based in Korea, said it would conduct a translational study with Johns Hopkins University School of Medicine to develop a combination therapy using its pipeline PHI-101 to treat relapsed or refractory acute myeloid leukemia (AML). A translational study involves the application of findings from basic scientific research to clinical or real-world settings in order to improve medical practice and patient outcomes. Pharos iBio’s corporate identity The Korean company and Donald Small, MD, Ph.D, a professor of pediatric oncology at Johns Hopkins who is a world-renowned expert in AML, will conduct the study to assess the efficacy of PHI-101 in combination with azacitidine (brand name: Vidasa) or venetoclax (brand names: Venclexta and Venclyxto), which are used as the first-line treatment of AML. Professor Small has over 30 years of research experience with FLT3, the target protein of PHI-101, and has led clinical studies of several FLT3 inhibitors in development, Pharos iBio said. He is also advising on the design and the U.S. clinical hospital network for the PHI-101 global phase 2 clinical trial in the U.S. The ongoing PHI-101 clinical trial is in a multinational phase 1b study in AML patients who have not responded to other existing drugs or whose disease has relapsed after treatment. On Aug. 2, Pharos iBio received approval from the Ministry of Food and Drug Safety “for the therapeutic use” of PHI-101 to treat relapsed or refractory AML. The therapeutic use approval allowed the Catholic University of Korea Seoul St. Mary’s Hospital, the applicant, to treat patients with relapsed or refractory AML on an individual basis. Pharos iBio has expanded the indications for PHI-101 by utilizing its AI-powered drug discovery platform, “Chemiverse.” Chemiverse utilizes the latest AI algorithms such as transformer generation models and big data of approximately 6.2 billion protein 3D structures and compounds. It is used in Pharos iBio's in-house drug discovery process to predict new targets, identify candidates, and expand indications. The Korean company is using Chemiverse to work on PHI-101 targeting AML, recurrent ovarian cancer, triple-negative breast cancer, and as a radiosensitizer. "PHI-101 for AML is our flagship pipeline, and we are preparing for a global phase 2 clinical trial, including the U.S., Australia, and Korea, targeted for the first half of 2024,” said Yoon Jeong-Hyuk Yoon, CEO of Pharos iBio. "The combination therapy translational study with Johns Hopkins University School of Medicine is also part of our 'One Source Multi-Use' strategy." Shares of Pharos iBio, listed on Kosdaq, were down 2.8 percent to trade at 15,270 won ($11.54) as of 11:28 a.m., Monday.
Pharos iBio Frequently Asked Questions (FAQ)
When was Pharos iBio founded?
Pharos iBio was founded in 2016.
Where is Pharos iBio's headquarters?
Pharos iBio's headquarters is located at 38, Heungan-daero 427beon-gil, Dongan-gu, Anyang.
What is Pharos iBio's latest funding round?
Pharos iBio's latest funding round is Series C.
How much did Pharos iBio raise?
Pharos iBio raised a total of $35.41M.
Who are the investors of Pharos iBio?
Investors of Pharos iBio include Company K Partners, Intops Investment, LSK Investment, Solidus Investment, TIMEFOLIO Asset Management and 12 more.